Novartis AG

York Central Hospital and Southlake Regional Health Centre are implementing the web-based Novari Surgical Access with Smart Wait system for wait list management, remote electronic operating room bookings and automation of provincial wait times reporting.

Abstral: SL opioid for breakthrough cancer pain and other new products.

Byetta: second GLP-1 agonist for diabetes; Gilenya: first oral disease-modifying drug for MS; Nucynta CR: new opioid for moderate—moderate/severe pain.

Product indicated for management of chronic pulmonary Pseudomonas aeruginosa infections in patients with cystic fibrosis, age six years or older.

Health Canada approves first disease-modifying oral treatment for multiple sclerosis in Canada.

New influenza vaccine with enhanced immunogenicity for patients 65 years and older.

Current deal dictates negotiation work must begin in April, discussions in May